Cellular events associated with the initial phase of AA amyloidogenesis: insights from a human monocyte model

References

• Benson M D. Amyloidosis. Arthritis and Allied Conditions, A Textbook of Rheumatology. 14th ed, W J Koopman. Lippencott, Williams, and Wilkins, Philadelphia, PA 2001; 1866–1895
   Google Scholar
• Husby G, Marhaug G, Dowton B, Sletten K, Sipe J D. Serum amyloid A (SAA): Biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid: Int J Clin Exp Invest 1994; 1: 119–137
   Web of Science ®Google Scholar
• Uhler C M, Whitehead A S. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999; 265: 501–523
   PubMedGoogle Scholar
• Hazenberg B CP. The changing face of AA amyloidosis. Amyloid and Amyloidosis, G Grateau, R A Kyle, M Skinner. CRC Press, Boca Raton, FL 2005; 517–520
   Google Scholar
• Kluve-Beckerman B, Liepnieks J J, Wang L, Benson M D. A cell culture system for the study of amyloid pathogenesis: Amyloid formation by peritoneal macrophages cultured with recombinant serum amyloid A. Am J Pathol 1999; 155: 123–133
   PubMed Web of Science ®Google Scholar
• Mackiewicz A, Kushner I, Baumann H. Acute phase proteins: molecular biology, biochemistry, and clinical applications. CRC Press, Boca Raton, FL 1993
   Google Scholar
• Jensen L E, Whitehead A S. Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J 1998; 334: 489–503
   PubMed Web of Science ®Google Scholar
• Steinmetz A, Hocke G, Saile R, Puchois P, Fruchart J C. Influence of serum amyloid A on cholesterol esterification in human plasma. Biochim Biophys Acta 1989; 1006: 173–178
   PubMed Web of Science ®Google Scholar
• Banka C L, Yuan T, de Beer M C, Kindy M, Curtiss L K, de Beer F C. Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J Lipid Res 1995; 36: 1058–1065
   PubMed Web of Science ®Google Scholar
• Liang J S, Schreiber B M, Salmona M, Phillip G, Gonnerman W A, de Beer F C, Sipe J D. Amino terminal region of acute phase, but not constitutive, serum amyloid A (apoSAA) specifically binds and transports cholesterol into aortic smooth muscle and HepG2 cells. J Lipid Res 1996; 37: 2109–2116
   PubMed Web of Science ®Google Scholar
• Lindhorst E, Young D, Bagshaw W, Hyland M, Kisilevsky R. Acute inflammation, acute phase serum amyloid A and cholesterol metabolism in the mouse. Biochim Biophys Acta 1997; 1339: 143–154
   PubMed Web of Science ®Google Scholar
• Pruzanski W, Stefanski E, de Beer F C, de Beer M C, Vadas P, Ravandi A, Kuksis A. Lipoproteins are substrates for human secretory group IIA phospholipase A2: preferential hydrolysis of acute phase HDL. J Lipid Res 1998; 39: 2150–2160
   PubMed Web of Science ®Google Scholar
• Schreiber B M. Serum amyloid A; in search of a function. Amyloid: J Protein Folding Disord 2002; 9: 279–280
   Google Scholar
• Tam S P, Flexman A, Hulme J, Kisilevsky R. Promoting export of macrophage cholesterol: the physiological role of a major acute-phase protein, serum amyloid A 2.1. J Lipid Res 2002; 43: 1410–1420
   PubMed Web of Science ®Google Scholar
• Badolato R, Wang J M, Murphy W J, Lloyd A R, Michiel D F, Bausserman L L, Kelvin D J, Oppenheim J J. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 1994; 180: 203–209
   PubMed Web of Science ®Google Scholar
• Su S B, Gong W H, Gao J L, Shen W, Murphy P M, Oppenheim J J, Wang J M. A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med 1999; 189: 395–402
   PubMed Web of Science ®Google Scholar
• Chronopoulos S, Laird D W, Ali-Khan Z. Immunolocalization of serum amyloid A and AA amyloid in lysosomes in murine monocytoid cells: Confocal and immunogold electron microscopic studies. J Pathol 1994; 173: 361–369
   PubMed Web of Science ®Google Scholar
• Chan S L, Chronopoulos S, Murray J, Laird D W, Ali-Khan Z. Selective localization of murine ApoSAA1/SAA2 in endosomes-lysosomes in activated macrophages and their degradation products. Amyloid: Int J Exp Clin Invest 1996; 4: 40–48
   Google Scholar
• Rocken C, Kisilevsky R. Comparison of the binding and endocytosis of high-density lipoprotein from healthy (HDL) and inflamed (HDLSAA) donors by murine macrophages of four different mouse strains. Virchows Arch 1998; 432: 547–555
   PubMed Web of Science ®Google Scholar
• Kluve-Beckerman B, Manaloor J J, Liepnieks J J. Binding, trafficking, and accumulation of serum amyloid A in peritoneal macrophages. Scand J Immunol 2001; 53: 393–400
   PubMed Web of Science ®Google Scholar
• Shirahama T S, Cohen A S. Intralysosomal formation of amyloid fibrils. Am J Pathol 1975; 81: 101–116
   PubMed Web of Science ®Google Scholar
• Takahashi M, Yokota T, Kawano H, Gondo T, Ishihara T, Uchino F. Ultrastructural evidence for intracellular formation of amyloid fibrils in macrophages. Virchows Arch A 1989; 415: 411–419
   Web of Science ®Google Scholar
• Miura K, Shirasawa H. Amyloid A (AA) fibril formation in renal tubules occurs intracytoplasmically, possibly at the site of membrane assembling structures. Amyloid: Int J Exp Clin Invest 1994; 1: 107–113
   Web of Science ®Google Scholar
• Westermark G T, Engstrom U, Westermark P. The N-terminal segment of protein AA determines its fibrillogenic property. Biochem Biophys Res Commun 1992; 182: 27–33
   PubMed Web of Science ®Google Scholar
• Yamada T, Kluve-Beckerman B, Liepnieks J J, Benson M D. Fibril formation from recombinant human serum amyloid A. Biochim Biophys Acta 1994; 1226: 323–329
   PubMed Web of Science ®Google Scholar
• Axelrad M A, Kisilevsky R, Willmer J, Chen S J, Skinner M. Further characterization of amyloid-enhancing factor. Lab Invest 1982; 47: 139–146
   PubMed Web of Science ®Google Scholar
• Kluve-Beckerman B, Manaloor J J, Liepnieks J J. A pulse-chase study tracking the conversion of macrophage-endocytosed serum amyloid A into extracellular amyloid. Arthritis Rheum 2002; 46: 1905–1913
   PubMedGoogle Scholar
• Elimova E, Kisilevsky R, Szarek W A, Ancsin J B. Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy. FASEB J 2004; 18: 1749–1751
   PubMed Web of Science ®Google Scholar
• Kluve-Beckerman B, Yamada T, Hardwick J, Liepnieks J J, Benson M D. Differential plasma clearance of murine acute phase serum amyloid A proteins, SAA1 and SAA2. Biochem J 1997; 322: 663–669
   PubMed Web of Science ®Google Scholar
• Schagger H, von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range of 1 to 100 kDa. Anal Biochem 1987; 166: 368–379
   PubMed Web of Science ®Google Scholar
• Puchtler H, Sweat F, Levine M. On the binding of Congo red by amyloid. J Histochem Cytochem 1962; 10: 355–364
   Web of Science ®Google Scholar
• Sipe J D, McAdam K PWJ, Uchino F. Biochemical evidence for the biphasic development of experimental amyloidosis. Lab Invest 1978; 38: 110–114
   PubMed Web of Science ®Google Scholar
• Lavie G, Zucker-Franklin D, Franklin E C. Elastase-type proteases on the surface of human blood monocytes: Possible role in amyloid formation. J Immunol 1980; 125: 175–180
   PubMed Web of Science ®Google Scholar
• Skogen B, Thorsteinsson L, Natvig J B. Degradation of protein SAA to an AA-like fragment by enzymes of monocytic origin. Scand J Immunol 1980; 11: 533–540
   PubMed Web of Science ®Google Scholar
• Elliott-Bryant R, Liang J S, Sipe J D, Cathcart E S. Degradation of serum amyloid A in amyloid-susceptible and amyloid-resistant mouse strains. Scand J Immunol 1996; 48: 223–228
   Google Scholar
• Ham D, Caouras V, Radzioch D, Gervais F. Degradation of amyloid A precursor protein SAA by macrophage cell lines obtained from amyloid resistant and susceptible strains of mice. Scand J Immunol 1997; 45: 354–360
   PubMedGoogle Scholar
• Migita K, Yamasaki S, Shibatomi K, Ida H, Kita M, Kawakami A, Eguchi K. Impaired degradation of serum amyloid A (SAA) protein by cytokine-stimulated monocytes. Clin Exp Immunol 2001; 123: 408–411
   PubMed Web of Science ®Google Scholar
• Phipps-Yonas H, Pinard G, Ali-Khan Z. Humoral proinflammatory cytokine and SAA generation profiles and spatio-temporal relationship between SAA and lysosomal cathepsin B and D in murine splenic monocytoid cells during AA amyloidosis. Scand J Immunol 2004; 59: 168–176
   PubMedGoogle Scholar
• Shirahama T, Miura K, Ju S T, Kisilevsky R, Gruys E, Cohen A S. Amyloid-enhancing factor-loaded macrophages in amyloid formation. Lab Invest 1990; 62: 61–68
   PubMed Web of Science ®Google Scholar
• Kisilevsky R, Narindrasorasak S, Tape C, Tan R, Boudreau L. During AA amyloidogenesis is proteolytic attack on serum amyloid A a pre- or post- fibrillogenic event?. Amyloid: Int J Exp Clin Invest 1994; 1: 174–183
   Web of Science ®Google Scholar
• Kawahara E, Shiroo M, Nakanishi I, Migita S. The role of fibronectin in the development of experimental amyloidosis. Evidence of immunohistochemical codistribution and binding property with serum amyloid protein A. Am J Pathol 1989; 134: 1305–1314
   PubMed Web of Science ®Google Scholar
• Magy N, Liepnieks J J, Benson M D, Kluve-Beckerman B. Amyloid-enhancing factor mediates amyloid formation on fibroblasts via a nidus/template mechanism. Arthritis Rheum 2003; 48: 1430–1437
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe D J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353–356
   PubMed Web of Science ®Google Scholar
• Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson C M, Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002; 416: 507–511
   PubMed Web of Science ®Google Scholar
• Kayed R, Head E, Thompson J L, McIntire T M, Milton S C, Cotman C W, Glabe C G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486–489
   PubMed Web of Science ®Google Scholar
• Reixach N, Deechongkit S, Jiang X, Kelly J W, Buxbaum J N. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA 2004; 101: 2817–2822
   PubMed Web of Science ®Google Scholar
• Blott E J, Griffiths G M. Secretory lysosomes. Nat Rev Mol Cell Biol 2002; 3: 122–131
   PubMed Web of Science ®Google Scholar
• de Gassart A, Geminard C, Hoekstra D, Vidal M. Exosome secretion: the art of reutilizing nonrecycled proteins?. Traffic 2004; 5: 896–903
   PubMed Web of Science ®Google Scholar
• Andrei C, Margiocco P, Poggi A, Lotti L V, Torrisi M R, Rubartelli A. Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes. Proc Natl Acad Sci USA 2004; 101: 9745–9750
   PubMed Web of Science ®Google Scholar
• Fevrier B, Vilette D, Laude H, Raposo G. Exosomes: a bubble ride for prions?. Traffic 2005; 6: 10–17
   PubMed Web of Science ®Google Scholar
• Kundra R, Kornfeld S. Asparagine-linked oligosaccharides protect Lamp-1 and Lamp-2 from intracellular proteolysis. J Biol Chem 1999; 274: 31039–31046
   PubMed Web of Science ®Google Scholar
• Ancsin J B. Amyloidogenesis: historical and modern observations point to heparan sulfate proteoglycans as a major culprit. Amyloid: J Protein Folding Disord 2003; 10: 67–79
   PubMed Web of Science ®Google Scholar
• McCubbin W D, Kay C M, Narindrasorasak S, Kisilevsky R. Circular-dichroism studies on two murine serum amyloid A proteins. Biochem J 1988; 256: 775–783
   PubMed Web of Science ®Google Scholar
• de Beer M C, de Beer F C, McCubbin W D, Kay C M, Kindy M S. Structural prerequisites for serum amyloid A fibril formation. J Biol Chem 1993; 268: 20606–20612
   PubMed Web of Science ®Google Scholar
• Kisilevsky R, Lemieux L J, Fraser P E, Kong X, Hultin P G, Szarek W A. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1995; 1: 143–148
   PubMed Web of Science ®Google Scholar
• Kisilevsky R, Szarek W A, Ancsin J B, Elimova E, Marone S, Bhat S, Berkin A. Inhibition of amyloid A amyloidogenesis in vivo and in tissue culture by 4-deoxy analogues of peracetylated 2-acetamido-2-deoxy-alpha- and beta-d-glucose: implications for the treatment of various amyloidoses. Am J Pathol 2004; 164: 2127–2137
   PubMed Web of Science ®Google Scholar
• Li J P, Galvis M L, Gong F, Zhang X, Zcharia E, Metzger S, Vlodavsky I, Kisilevsky R, Lindahl U. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci USA 2005; 102: 6473–6477
   PubMed Web of Science ®Google Scholar
• Sugumaran G, Elliott-Bryant R, Phung N, Vitseva O, Kuberan B, Lech M. Characterization of splenic glycosaminoglycans accumulated in vivo in experimentally induced amyloid-susceptible and amyloid-resistant mice. Scand J Immunol 2004; 60: 574–583
   PubMed Web of Science ®Google Scholar